Bioxel Pharma, Inc. has entered into two separate letters of intent with companies specialized in pharmaceutical API manufacturing. Under the terms of the agreements, these companies will perform the commercial scale-up of specific steps of Bioxel’s manufacturing process for semi-synthetic taxanes. “These agreements represent a key milestone in the industrial scale-up of our technologies and the commercialization of our new taxane products,” said Pascal Delmas, president a...